Mathematical methods to determine quantitative parameters of myocardial 123I-MIBG studies: A review of the literature

Nuclear Medicine Communications

Volumn 31, Issue 7, 2010, Pages 617-628

  Van Der Veen, Linda ^a   Scholte, Arthur ^a   Stokkel, Marcel ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

123I meta iodobenzyl guanidine; Myocardial innervation; Quantitative analysis; Review

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123;

CLINICAL PROTOCOL; COMPARATIVE STUDY; HEART INNERVATION; HEART SCINTISCANNING; IMAGE ANALYSIS; MATHEMATICAL ANALYSIS; MEDIASTINUM; MEDICAL LITERATURE; NORMAL VALUE; REFERENCE VALUE; REVIEW; STANDARDIZATION; SYMPATHETIC NERVE;

3-IODOBENZYLGUANIDINE; HEART; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MEDIASTINUM; MYOCARDIUM; RADIONUCLIDE IMAGING;

EID: 77953363269     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328337a99b     Document Type: Review

References (65)

1. Carrio I. Cardiac neurotransmission imaging. J Nucl Med 2001; 42:1062-1076.
2. Eisenhofer G, Pacak K, Goldstein DS, Chen C, Shulkin B. 123I-MIBG scintigraphy of catecholamine systems: impediments to applications in clinical medicine. Eur J Nucl Med 2000; 27:611-612.
3. Hattori N, Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart: what have we learnt clinically? Eur J Nucl Med 2000; 27:1-6.
4. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 2008; 29:1147-1159.
5. Agostini D, Carrio I, Verberne HJ. How to use myocardial 123I-MIBG scintigraphy in chronic heart failure. Eur J Nucl Med Mol Imaging 2009; 36:555-559.
6. Verberne HJ, Habraken JB, van Eck-Smit BL, Agostini D, Jacobson AF. Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation. Eur J Nucl Med Mol Imaging 2008; 35:547-553.
7. Yamashina S, Yamazaki J. Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging 2007; 34:939-950. (Pubitemid 46798959)
8. Kasama S, Toyama T, Sumino H, Nakazawa M, Matsumoto N, Sato Y, et al. Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med 2008; 49:907-914.
9. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, et al. Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol. Eur Heart J 2007; 28:989-995.
10. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2007; 49:667-674.
11. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart 2006; 92:1434-1440.
12. Nanjo S, Yamashiro Y, Fujimoto S, Yamashina S, Nakanishi R, Fukunaga S, et al. Evaluation of sympathetic activity by 123I-metaiodobenzylguanidine myocardial scintigraphy in dilated cardiomyopathy patients with sleep breathing disorder. Circ J 2009; 73:686-690.
13. Lorincz I, Garai I, Varga E, Barta K, Simko J, Szabo Z, et al. Myocardial adrenergic innervation in patients with vasovagal syncope measured with 123I-MIBG uptake. Nucl Med Commun 2009; 30:134-139.
14. Momose M, Kobayashi H, Iguchi N, Matsuda N, Sakomura Y, Kasanuki H, et al. Comparison of parameters of 123I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. Nucl Med Commun 1999; 20:529-535.
15. Tamaki S, Yamada T, Okuyama Y, Morita T, Sanada S, Tsukamoto Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 2009; 53:426-435.
16. Ogita H, Shimonagata T, Fukunami M, Kumagai K, Yamada T, Asano Y, et al. Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart 2001; 86:656-660.
17. Toyama T, Seki R, Kasama S, Isobe N, Sakurai S, Adachi H, et al. Effectiveness of nocturnal home oxygen therapy to improve exercise capacity, cardiac function and cardiac sympathetic nerve activity in patients with chronic heart failure and central sleep apnea. Circ J 2009; 73:299-304.
18. Toyama T, Aihara Y, Iwasaki T, Hasegawa A, Suzuki T, Nagai R, et al. Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin- converting enzyme inhibitor therapy. J Nucl Med 1999; 40:217-223.
19. Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997; 38:1085-1089.
20. Sakata K, Iida K, Mochizuki N, Ito M, Nakaya Y. Physiological changes in human cardiac sympathetic innervation and activity assessed by (123)Imetaiodobenzylguanidine (MIGB) imaging. Circ J 2009; 73:310-315.
21. Sakata K, Shirotani M, Yoshida H, Kurata C. Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension. J Am Coll Cardiol 1998; 32:438-443.
22. Spinelli A, Lanza GA, Calcagni ML, Sestito A, Sgueglia GA, Di MA, et al. Effect of spinal cord stimulation on cardiac adrenergic nerve function in patients with cardiac syndrome X. J Nucl Cardiol 2008; 15:804-810.
23. Lanza GA, Giordano A, Pristipino C, Calcagni ML, Meduri G, Trani C, et al. Abnormal cardiac adrenergic nerve function in patients with syndrome X detected by [123I]metaiodobenzylguanidine myocardial scintigraphy. Circulation 1997; 96:821-826.
24. Giordano A, Calcagni ML, Rufini V, Colivicchi F, Melina D, Melina G, et al. Use of [123I]MIBG to assess cardiac adrenergic innervation: experience in hypertensive cardiopathy and left ventricular aneurysms. Q J Nucl Med 1995; 39 (4 Suppl 1):44-48.
25. Tsutamoto T, Nishiyama K, Sakai H, Tanaka T, Fujii M, Yamamoto T, et al. Transcardiac increase in norepinephrine and prognosis in patients with chronic heart failure. Eur J Heart Fail 2008; 10:1208-1214.
26. Kioka H, Yamada T, Mine T, Morita T, Tsukamoto Y, Tamaki S, et al. Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart 2007; 93:1213-1218.
27. Matsui T, Tsutamoto T, Maeda K, Kusukawa J, Kinoshita M. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments-comparison with neurohumoral factors. Circ J 2002; 66:537-543.
28. Tateno M, Kobayashi S, Shirasaka T, Furukawa Y, Fujii K, Morii H, et al. Comparison of the usefulness of brain perfusion SPECT and MIBG myocardial scintigraphy for the diagnosis of dementia with Lewy bodies. Dement Geriatr Cogn Disord 2008; 26:453-457.
29. Yoshita M, Taki J, Yokoyama K, Noguchi-Shinohara M, Matsumoto Y, Nakajima K, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 2006; 66:1850-1854.
30. Hanyu H, Shimizu S, Hirao K, Sakurai H, Iwamoto T, Chikamori T, et al. The role of 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic. Dement Geriatr Cogn Disord 2006; 22:379-384.
31. Shibata M, Morita Y, Shimizu T, Takahashi K, Suzuki N. Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson's disease. J Neurol Sci 2009; 276:79-83.
32. Estorch M, Camacho V, Paredes P, Rivera E, Rodriguez-Revuelto A, Flotats A, et al. Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging 2008; 35:1636-1641.
33. Estorch M, Carrio I, Berna L, Lopez-Pousa J, Torres G. Myocardial iodinelabeled metaiodobenzylguanidine 123 uptake relates to age. J Nucl Cardiol 1995; 2 (2 Pt 1):126-132.
34. Cha YM, Oh J, Miyazaki C, Hayes DL, Rea RF, Shen WK, et al. Cardiac resynchronization therapy upregulates cardiac autonomic control. J Cardiovasc Electrophysiol 2008; 19:1045-1052.
35. Somsen GA, Verberne HJ, Fleury E, Righetti A. Normal values and withinsubject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies. J Nucl Cardiol 2004; 11:126-133.
36. Tsutamoto T, Tanaka T, Sakai H, Nishiyama K, Fujii M, Yamamoto T, et al. Beneficial effect of perindopril on cardiac sympathetic nerve activity and brain natriuretic peptide in patients with chronic heart failure: comparison with enalapril. Circ J 2008; 72:740-746.
37. Diakakis GF, Parthenakis FI, Patrianakos AP, Koukouraki SI, Stathaki MI, Karkavitsas NS, et al. Myocardial sympathetic innervation in patients with impaired glucose tolerance: relationship to subclinical inflammation. Cardiovasc Pathol 2008; 17:172-177.
38. Burri H, Sunthorn H, Somsen A, Fleury E, Stettler C, Shah D, et al. Improvement in cardiac sympathetic nerve activity in responders to resynchronization therapy. Europace 2008; 10:374-378. (Pubitemid 351773736)
39. Ohshima S, Isobe S, Izawa H, Nanasato M, Ando A, Yamada A, et al. Cardiac sympathetic dysfunction correlates with abnormal myocardial contractile reserve in dilated cardiomyopathy patients. J Am Coll Cardiol 2005; 46:2061-2068.
40. Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol 2003; 41:231-238.
41. Lorberboym M, Lampl Y, Nikolov G, Sadeh M, Gilad R. I-123 MIBG cardiac scintigraphy and autonomic test evaluation in multiple sclerosis patients. J Neurol 2008; 255:211-216.
42. Verberne HJ, Sokole EB, Van Moerkerken AF, Deeterink JH, Ensing G, Stabin MG, et al. Clinical performance and radiation dosimetry of no-carrieradded versus carrier-added 123I-metaiodobenzylguanidine (MIBG) for the assessment of cardiac sympathetic nerve activity. Eur J Nucl Med Mol Imaging 2008; 35:798-807.
43. Nagamatsu H, Momose M, Kobayashi H, Kusakabe K, Kasanuki H. Prognostic value of 123I-metaiodobenzylguanidine in patients with various heart diseases. Ann Nucl Med 2007; 21:513-520.
44. Nishioka SA, Martinelli FM, Brandao SC, Giorgi MC, Vieira ML, Costa R, et al. Cardiac sympathetic activity pre and post resynchronization therapy evaluated by 123I-MIBG myocardial scintigraphy. J Nucl Cardiol 2007; 14:852-859.
45. Tsukamoto T, Morita K, Naya M, Inubushi M, Katoh C, Nishijima K, et al. Decreased myocardial beta-adrenergic receptor density in relation to increased sympathetic tone in patients with nonischemic cardiomyopathy. J Nucl Med 2007; 48:1777-1782.
46. Gould PA, Kong G, Kalff V, Duffy SJ, Taylor AJ, Kelly MJ, et al. Improvement in cardiac adrenergic function post biventricular pacing for heart failure. Europace 2007; 9:751-756.
47. Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Rande JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999; 40:917-923.
48. Furuhashi T, Moroi M. Importance of renal function on prognostic value of cardiac iodine-123 metaiodobenzylguanidine scintigraphy. Ann Nucl Med 2007; 21:57-63.
49. Arimoto T, Takeishi Y, Niizeki T, Nozaki N, Hirono O, Watanabe T, et al. Cardiac sympathetic denervation and ongoing myocardial damage for prognosis in early stages of heart failure. J Card Fail 2007; 13:34-41.
50. Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M,Watanabe K. Prognostic value of iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ J 2001; 65:155-160.
51. Pessoa PM, Xavier SS, Lima SL, Mansur J, de Almeida AS, Carvalho PA, et al. Assessment of takotsubo (ampulla) cardiomyopathy using iodine-123 metaiodobenzylguanidine scintigraphy. Acta Radiol 2006; 47:1029-1035.
52. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155:60-67.
53. Yoshita M, Hayashi M, Hirai S. Decreased myocardial accumulation of 123I-meta-iodobenzyl guanidine in Parkinson's disease. Nucl Med Commun 1998; 19:137-142.
54. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003; 41:574-581.
55. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002; 43:1279-1285.
56. Kasama S, Toyama T, Hoshizaki H, Oshima S, Taniguchi K, Suzuki T, et al. Dobutamine gated blood pool scintigraphy predicts the improvement of cardiac sympathetic nerve activity, cardiac function, and symptoms after treatment in patients with dilated cardiomyopathy. Chest 2002; 122:542-548.
57. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 2003; 44:884-890.
58. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33:471-477.
59. Sugiura M, Yamamoto K, Takeda Y, Takeda Y, Dohmori T, Ogata M, et al. The relationship between variables of 123-I-metaiodobenzylguanidine cardiac imaging and clinical status of the patients with diastolic heart failure. Int J Cardiol 2006; 113:223-228.
60. Inoue Y, Suzuki A, Shirouzu I, Machida T, Yoshizawa Y, Akita F, et al. Effect of collimator choice on quantitative assessment of cardiac iodine 123 MIBG uptake. J Nucl Cardiol 2003; 10:623-632.
61. Verberne HJ, Feenstra C, de Jong WM, Somsen GA, van Eck-Smit BL, Busemann SE. Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging 2005; 32:1100-1107.
62. Glowniak JV. Cardiac studies with metaiodobenzylguanidine: a critique of methods and interpretation of results. J Nucl Med 1995; 36:2133-2137.
63. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008; 35:535-546.
64. Kiyono Y, Kanegawa N, Kawashima H, Iida Y, Kinoshita T, Tamaki N, et al. Age-related changes of myocardial norepinephrine transporter density in rats: implications for differential cardiac accumulation of MIBG in aging. Nucl Med Biol 2002; 29:679-684.
65. Tsuchimochi S, Tamaki N, Tadamura E, Kawamoto M, Fujita T, Yonekura Y, et al. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging. J Nucl Med 1995; 36:969-974.